Dark

Check out our Level2View

FLXN
Horizon Flexible Income ETF
stock BATS ETF

At Close

Dec 17, 2025 11:09:57 AM EST

25.97USD0.000%(+25.97)1,712

0.00Bid 0.00Ask 0.00Spread

Pre-market

0.00USD-100.000%(0.00)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Nov 19, 2021

10:09AM EST Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021 Benzinga

08:58AM EST Northland Capital Markets Downgrades Flexion Therapeutics to Market Perform Benzinga

08:40AM EST -- Adds highly complementary ZILRETTA to Pacira commercial offering -- GlobeNewswire Inc

Nov 2, 2021

06:35PM EDT LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Flexion Therapeutics, Inc. - FLXN PR Newswire

Oct 19, 2021

12:06PM EDT What 5 Analyst Ratings Have To Say About Flexion Therapeutics Benzinga

10:02AM EDT Benzinga's Top Ratings Upgrades, Downgrades For October 19, 2021 Benzinga

06:26AM EDT HC Wainwright & Co. Downgrades Flexion Therapeutics to Neutral, Lowers Price Target to $10 Benzinga

Oct 12, 2021

12:27PM EDT Analyst Ratings For Flexion Therapeutics Benzinga

12:25PM EDT FLEXION THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Flexion Therapeutics, Inc. - FLXN Business Wire

10:48AM EDT Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2021 Benzinga

08:13AM EDT The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology Benzinga

07:32AM EDT 10 Biggest Price Target Changes For Tuesday Benzinga

07:26AM EDT BMO Capital Downgrades Flexion Therapeutics to Market Perform, Lowers Price Target to $12 Benzinga

06:19AM EDT Raymond James Downgrades Flexion Therapeutics to Market Perform Benzinga

06:17AM EDT Credit Suisse Downgrades Flexion Therapeutics to Neutral, Lowers Price Target to $10 Benzinga

Oct 11, 2021

03:17PM EDT Mid-Afternoon Market Update: Dow Tumbles Over 100 Points; Flexion Therapeutics Shares Spike Higher Benzinga

12:13PM EDT Mid-Day Market Update: Crude Oil Surges Over 2%; Supernus Pharmaceuticals To Acquire Adamas Pharmaceuticals Benzinga

07:45AM EDT Pacira BioSciences, Inc. (PCRX) and Flexion Therapeutics, Inc. (FLXN) announced Monday a definitive agreement pursuant to which Pacira will acquire Flexion for $8.50 per share in cash, plus one non-tradeable contingent value right (CVR) worth up to $8.00 per share in cash. RTTNews

07:30AM EDT Pacira To Buy Flexion For $8.50/shr Cash, Plus One Non-tradeable CVR Worth Up To $8/shrcash RTTNews

07:16AM EDT Flexion Therapeutics, Inc. Shares To Resume Trade At 7:30 a.m. ET Benzinga

07:01AM EDT Pacira BioSciences to Acquire Flexion Therapeutics For $8.50/Share In Cash Plus One Non-tradeable Contingent Value Right Worth Up To $8/Share In Cash Benzinga

07:00AM EDT -- Adds highly complementary ZILRETTA to Pacira commercial offering -- GlobeNewswire Inc

Oct 1, 2021

04:30PM EDT Flexion Therapeutics Reports Inducement Grants GlobeNewswire Inc

Sep 8, 2021

04:30PM EDT Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in a virtual analyst-led fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference taking place September 13-15, 2021. GlobeNewswire Inc

Sep 3, 2021

09:00AM EDT Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the Wells Fargo 2021 Virtual Healthcare Conference.The virtual fireside chat is scheduled to begin at 4:35 p.m. ET on Thursday, September 9, 2021. GlobeNewswire Inc

Sep 2, 2021

07:32AM EDT Flexion Therapeutics Reports Inclusion Of ZILRETTA In American Academy Of Orthopaedic Surgeons Clinical Practice Guidelines For Mgmt. Of Osteoarthritis Of The Knee Benzinga

07:30AM EDT -- AAOS finds that ZILRETTA (triamcinolone acetonide extended-release injectable suspension) can improve patient outcomes over immediate-release corticosteroids GlobeNewswire Inc

Aug 25, 2021

07:37AM EDT Flexion Therapeutics Announces Expansion Of Phase 1b Trial Investigating FX301 For Management Of Post-Operative Pain RTTNews

07:33AM EDT Flexion Therapeutics Announces Expansion of Phase 1b Trial Investigating FX301 for the Management of Post-Operative Pain Benzinga

07:30AM EDT -- Initial findings from proof-of-concept trial in patients undergoing bunionectomy support expansion of the study to include 36 additional patients -- Data from the trial, including the expansion cohort, anticipated by year-end GlobeNewswire Inc

Aug 20, 2021

07:45AM EDT The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data Benzinga

Aug 19, 2021

10:57AM EDT The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck Benzinga

Aug 18, 2021

07:38AM EDT The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline Benzinga

Aug 17, 2021

08:28AM EDT The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business Benzinga

Aug 13, 2021

07:43AM EDT The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO Benzinga

Aug 10, 2021

07:55AM EDT The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts Benzinga

Aug 9, 2021

04:30PM EDT Flexion Therapeutics Announces Publication Of Results From Phase 2 Pharmacokinetics (PK) And Safety Study Of ZILRETTA In Shoulder Osteoarthritis (OA) Benzinga

Aug 6, 2021

08:23AM EDT Goldman Sachs Maintains Neutral on Flexion Therapeutics, Lowers Price Target to $6 Benzinga

Aug 5, 2021

08:08AM EDT The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO Benzinga

06:53AM EDT Needham Maintains Buy on Flexion Therapeutics, Lowers Price Target to $18 Benzinga

Aug 4, 2021

04:27PM EDT Flexion Therapeutics Q2 EPS $(0.44) Up From $(0.76) YoY, Sales $28.18M Miss $29.01M Estimate Benzinga

04:01PM EDT Flexion Therapeutics Reports Second-Quarter 2021 Financial GlobeNewswire Inc

07:52AM EDT The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings Benzinga

04:10AM EDT Earnings Scheduled For August 4, 2021 Benzinga

Aug 1, 2021

11:19AM EDT The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs Benzinga

Jul 28, 2021

07:33AM EDT The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal Benzinga

Jul 27, 2021

11:13AM EDT The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts Benzinga

Jul 20, 2021

08:20AM EDT The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street Benzinga

Jul 16, 2021

07:37AM EDT The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study Benzinga

Jul 12, 2021

04:32PM EDT Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the appointment of Utpal Koppikar, Chief Financial Officer of Atara Biotherapeutics, to its Board of Directors. Mr. Koppikar will serve as the chair of Flexions audit committee. GlobeNewswire Inc

Jul 2, 2021

04:30PM EDT Flexion Therapeutics Reports Inducement Grants Under Nasdaq GlobeNewswire Inc

Jun 14, 2021

04:30PM EDT Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the 2021 Raymond James Human Health Innovation Conference. The virtual fireside chat is scheduled to begin at3:20 p.m. ET on Monday, June 21, 2021. GlobeNewswire Inc

Jun 10, 2021

08:13AM EDT The Daily Biotech Pulse: US To Procure 500M Pfizer-BioNTech Vaccine Doses For Donation, Verona Out-Licenses COPD Drug, Nautilus Lists Through SPAC Deal Benzinga

Jun 9, 2021

04:15PM EDT Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that William T. Andrews, M.D., F.A.C.P., will join the company as Chief Medical Officer (CMO), effective July 1, 2021. GlobeNewswire Inc

Jun 4, 2021

04:30PM EDT Flexion Therapeutics Reports Inducement Grants Under Nasdaq GlobeNewswire Inc

Jun 2, 2021

04:30PM EDT Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Virtual Conference.The virtual fireside chat is scheduled to begin at3:50 p.m. ET on Tuesday, June 8, 2021. GlobeNewswire Inc

May 28, 2021

11:09AM EDT Return On Capital Employed Overview: Flexion Therapeutics Benzinga

May 13, 2021

04:30PM EDT Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the RBC Capital Markets 2021 Virtual Global Healthcare Conference.The virtual fireside chat is scheduled to begin at1:55 p.m. ET on Wednesday, May 19, 2021. GlobeNewswire Inc

11:54AM EDT Credit Suisse Maintains Outperform on Flexion Therapeutics, Lowers Price Target to $14 Benzinga

May 12, 2021

05:05PM EDT Flexion Therapeutics: Q1 Earnings Insights Benzinga

04:14PM EDT Flexion Therapeutics Q1 EPS $(0.57) Misses $(0.52) Estimate, Sales $28.60M Beat $24.77M Estimate Benzinga

04:01PM EDT Flexion Therapeutics Reports First-Quarter 2021 Financial Results GlobeNewswire Inc

08:57AM EDT The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron Benzinga

04:22AM EDT Earnings Scheduled For May 12, 2021 Benzinga

May 11, 2021

12:56PM EDT Earnings Preview: Flexion Therapeutics Benzinga

08:53AM EDT Benzinga Pro's Top 5 Stocks To Watch For Tuesday, May 11, 2021: GLD, AMC, COIN, HRTX, FLXN Benzinga

07:54AM EDT The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings Benzinga

May 7, 2021

04:30PM EDT Flexion Therapeutics Reports Inducement Grants Under Nasdaq GlobeNewswire Inc

May 5, 2021

07:43AM EDT The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues Benzinga

May 4, 2021

08:10AM EDT The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data Benzinga

Apr 29, 2021

08:15AM EDT The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx Benzinga

Apr 28, 2021

08:01AM EDT Flexion Therapeutics Announces Presentation Of Preliminary FX201 Clinical Data At Upcoming 2021 American Society Of Gene And Cell Therapy Annual Meeting Benzinga

07:30AM EDT Flexion Therapeutics Announces Presentation of Preliminary FX201 GlobeNewswire Inc

Apr 14, 2021

10:09AM EDT Flexion Therapeutics shares were trading higher after the company issued Q1 and FY21 ZILRETTA sales guidance. Raymond James also maintained a Strong Buy rating on the stock. Benzinga

08:17AM EDT Credit Suisse Maintains Outperform on Flexion Therapeutics, Lowers Price Target to $17 Benzinga

07:51AM EDT The Daily Biotech Pulse: Novavax CFO Departs, Zai Lab Inks Cancer Drug Collaboration, FDA Nod For Gilead Benzinga

07:22AM EDT Raymond James Maintains Strong Buy on Flexion Therapeutics, Lowers Price Target to $16 Benzinga

Apr 13, 2021

04:02PM EDT Flexion Therapeutics Sees Prelim. Q1 ZILRETTA Net Sales $24.6M, FY21 ZILRETTA Net Sales $120M-$130M Benzinga

04:01PM EDT -- First-quarter ZILRETTA net sales estimated to be approximately $24.6million -- 2021 full-year ZILRETTA net sales anticipated to be in the range of $120million to $130million and total operating expenses expected between $195million to $205million -- Company to hold conference call today at 4:30 p.m. ET GlobeNewswire Inc

Apr 8, 2021

04:31PM EDT Flexion Therapeutics To Present At Needham 20th Annual Virtual Healthcare Conference Apr. 15 Benzinga

04:30PM EDT Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the Needham 20th Annual Healthcare Conference. The virtual fireside chat is scheduled to begin at9:30 a.m. ET on Thursday, April 15, 2021. GlobeNewswire Inc

Apr 2, 2021

04:30PM EDT Flexion Therapeutics Reports Inducement Grants Under Nasdaq GlobeNewswire Inc

Mar 31, 2021

07:38AM EDT Flexion Therapeutics Says First Patient Treated In FX301 Phase 1b Trial RTTNews

07:32AM EDT Flexion Therapeutics Announces First Patient Treated in FX301 Phase 1b Trial for Management of Post-Operative Pain Benzinga

07:30AM EDT -- FX301 is a locally administered NaV1.7 inhibitor (funapide) formulated for extended release in a proprietary thermosensitive hydrogel -- Proof-of-concept trial will evaluate safety and tolerability of FX301 administered as a peripheral analgesic nerve block in patients undergoing bunionectomy; initial data anticipated later this year GlobeNewswire Inc

Mar 15, 2021

09:00AM EDT Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the Oppenheimer 31st Annual Healthcare Conference. The virtual fireside chat is scheduled to begin at10:00 a.m. ET on Wednesday, March 17, 2021. GlobeNewswire Inc

Mar 11, 2021

11:23AM EST Credit Suisse Maintains Outperform on Flexion Therapeutics, Lowers Price Target to $18 Benzinga

Mar 10, 2021

04:22PM EST Flexion Therapeutics: Q4 Earnings Insights Benzinga

04:04PM EST Flexion Therapeutics FY20 Net Loss $113.7M Benzinga

04:01PM EST Flexion Therapeutics Reports Fourth-Quarter and Full-Year 2020 GlobeNewswire Inc

07:26AM EST The Daily Biotech Pulse: MediciNova Bags BARDA Contract, Lilly's COVID-19 Antibody Cocktail Data, Bluebird Bio Refutes Blood Cancer Link Benzinga

04:04AM EST Earnings Scheduled For March 10, 2021 Benzinga

Mar 6, 2021

10:58AM EST The Week Ahead In Biotech (March 7-13): Conference Presentations And More Earnings Benzinga

Mar 5, 2021

04:30PM EST Flexion Therapeutics Reports Inducement Grants Under Nasdaq GlobeNewswire Inc

Mar 3, 2021

04:30PM EST Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its fourth-quarter and full-year 2020 financial results after the close of the U.S. financial markets on Wednesday, March 10, 2021. GlobeNewswire Inc

Mar 1, 2021

12:58PM EST Flexion Therapeutics To Start Testing FX301 For Post-Op Pain In Patients After Musculoskeletal Surgery Benzinga

07:38AM EST Flexion Therapeutics: FDA Clears IND Application For FX301 For Post-Operative Pain RTTNews

07:31AM EST Flexion Therapeutics Announces FDA Clearance Of Investigational New Drug Application For FX301 In Post-Operative Pain Benzinga

07:30AM EST Flexion Therapeutics Announces FDA Clearance of Investigational GlobeNewswire Inc

Feb 22, 2021

04:30PM EST Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the 42nd Annual Raymond James Institutional Investors Conference. The virtual fireside chat is scheduled to begin at12:30 p.m. ET on Monday, March 1, 2021. GlobeNewswire Inc

Feb 18, 2021

02:15PM EST Flexion To Test Higher Dose Of FX201 Gene Therapy In Early-Stage Osteoarthritis Study Benzinga

07:34AM EST Flexion Therapeutics To Advance Investigational Gene Therapy FX201 Into High Dose Cohort Of Phase 1 Clinical Trial In Knee Osteoarthritis And Expand Low And Mid Dose Treatment Groups Benzinga

07:30AM EST Flexion Therapeutics to Advance Investigational Gene Therapy FX201 GlobeNewswire Inc

Feb 1, 2021

09:10AM EST Flexion Therapeutics Reports Partnership With Form WNBA Player, Sheryl Swoopes, To Raise Awareness Of ZILRETTA Benzinga

09:00AM EST National Basketball Retired Players Association, Sheryl Swoopes GlobeNewswire Inc

Jan 27, 2021

06:24AM EST Wells Fargo Maintains Overweight on Flexion Therapeutics, Lowers Price Target to $15 Benzinga

Jan 13, 2021

07:07AM EST Flexion Therapeutics Sees Q4 ZILRETTA Net Sales To Be About $26.3 Mln RTTNews

07:02AM EST Flexion Therapeutics Sees Q4 ZILRETTA Net Sales ~26.3M; FY20 Net Sales ~85.5M Benzinga

07:00AM EST -- Fourth-quarter 2020ZILRETTA(triamcinolone acetonide extended-release injectable suspension) net sales estimated to be approximately $26.3million -- Full-year 2020 net sales estimated to be approximately $85.5million -- Company names Adam Muzikant, Ph.D., Chief Business Officer GlobeNewswire Inc

Jan 7, 2021

04:30PM EST Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the ICR | Westwicke Investment Conference.The virtual fireside chat is scheduled to begin at 10:45 a.m. ET on Thursday, January 14, 2021. GlobeNewswire Inc

Dec 7, 2020

04:30PM EST Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the Needham Virtual Epilepsy and Pain Specialty CNS Therapeutics Conference.The virtual fireside chat is scheduled to begin at 2:15 p.m. ET on Friday, December 11, 2020. GlobeNewswire Inc

Dec 4, 2020

04:30PM EST Flexion Therapeutics Reports Inducement Grants Under Nasdaq GlobeNewswire Inc

Nov 5, 2020

09:02AM EST Raymond James Maintains Strong Buy on Flexion Therapeutics, Lowers Price Target to $18 Benzinga

07:38AM EST BMO Capital Maintains Outperform on Flexion Therapeutics, Lowers Price Target to $22 Benzinga

Nov 4, 2020

04:33PM EST Flexion Therapeutics: Q3 Earnings Insights Benzinga

04:08PM EST Flexion Therapeutics Q3 EPS $(0.50) Beats $(0.51) Estimate, Sales $23.66M Beat $23.48M Estimate Benzinga

04:01PM EST -- Companyreported ZILRETTA (triamcinolone acetonide extended-release injectable suspension) net sales of $23.7million in third quarter 2020 GlobeNewswire Inc

08:21AM EST The Daily Biotech Pulse: Alzheimer's Conference Underway, Biogen's Aducanumab Briefing Doc, Supernus Earnings Benzinga

04:41AM EST Earnings Scheduled For November 4, 2020 Benzinga

Nov 1, 2020

09:40AM EST The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings Benzinga

Oct 13, 2020

07:00AM EDT Flexion Therapeutics Sees Prelim. Q3 Net Sales Of ZILRETTA ~$23.6M Benzinga

06:59AM EDT Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced preliminary ZILRETTA(triamcinolone acetonide extended-release injectable suspension) net sales of $23.6 million for the quarter ended September 30, 2020. GlobeNewswire Inc

Oct 8, 2020

04:30PM EDT Flexion Therapeutics to Present at the 2020 Cell & Gene Virtual GlobeNewswire Inc

Oct 5, 2020

09:06AM EDT Flexion Therapeutics Announces Podium Presentation Of FX301 Preclinical Data At Virtual ANESTHESIOLOGY 2020 Meeting At 11:00 a.m. ET Benzinga

09:00AM EDT -- Previously presented preclinical findings show FX301 provided greater sustained, post-operative analgesic effect with no significant impairment in motor function compared to liposomal bupivacaine and placebo GlobeNewswire Inc

Oct 2, 2020

04:30PM EDT Flexion Therapeutics Reports Inducement Grants Under Nasdaq GlobeNewswire Inc

Sep 9, 2020

04:30PM EDT Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the H.C. Wainwright Virtual Healthcare Conference.The virtual fireside chat is scheduled to begin at 10:00 a.m. ET on Tuesday, September 15, 2020. GlobeNewswire Inc

Sep 8, 2020

04:31PM EDT Flexion Therapeutics Highlights Treatment Of First Patient In Second Cohort Of FX201 Phase 1 Dose-Escalation Trial Benzinga

04:30PM EDT -- Five patients treated in first cohort of Phase 1 clinical trial evaluating the safety and tolerability of FX201; Drug Monitoring Committee (DMC) supported the initiation of the next dosing cohort GlobeNewswire Inc

Sep 4, 2020

04:30PM EDT Flexion Therapeutics Reports Inducement Grants Under Nasdaq GlobeNewswire Inc

Sep 3, 2020

04:30PM EDT Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the Wells Fargo 2020 Virtual Healthcare Conference.The virtual fireside chat is scheduled to begin at 10:40 a.m. ET on Wednesday, September 9, 2020. GlobeNewswire Inc

Aug 20, 2020

09:51AM EDT Benzinga's Top Upgrades, Downgrades For August 20, 2020 Benzinga

06:26AM EDT Goldman Sachs Initiates Coverage On Flexion Therapeutics with Neutral Rating, Announces Price Target of $15 Benzinga

Aug 19, 2020

09:08AM EDT Flexion Therapeutics Appoints Elizabeth Kwo To Its Board RTTNews

09:00AM EDT Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the appointment of Elizabeth (Liz) Kwo, MD, Staff Vice President, Clinical Data Analytics at Anthem, to its Board of Directors. GlobeNewswire Inc

Aug 7, 2020

04:30PM EDT Flexion Therapeutics Reports Inducement Grants Under Nasdaq GlobeNewswire Inc

Aug 5, 2020

04:01PM EDT -- Company reportedZILRETTA(triamcinolone acetonide extended-release injectable suspension) net sales of$15.5 millionin second quarter 2020 -- Flexion resumed enrollment in Phase 1 dose-escalation trial for FX201; FX301 on track to enter clinic in 2021 GlobeNewswire Inc

04:21AM EDT Earnings Scheduled For August 5, 2020 Benzinga

Jul 31, 2020

01:03PM EDT Oppenheimer Initiates Coverage On Flexion Therapeutics with Outperform Rating, Announces Price Target of $19 Benzinga

Jul 29, 2020

09:38AM EDT Benzinga's Top Upgrades, Downgrades For July 29, 2020 Benzinga

07:49AM EDT Credit Suisse Initiates Coverage On Flexion Therapeutics with Outperform Rating, Announces Price Target of $19 Benzinga

Jul 14, 2020

07:00AM EDT Flexion Therapeutics Sees Prelim. Q2 ZILRETTA Net Sales $15.4M Benzinga

06:59AM EDT Flexion Therapeutics Announces Preliminary Second-Quarter 2020 GlobeNewswire Inc

Share